Suppr超能文献

唐氏综合征治疗研究的口语语言结局评估指标:来自表达性语言取样的变量的可行性、练习效应、重测信度和结构效度。

Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling.

机构信息

MIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA.

Department of Psychiatry and Behavioral Sciences, University of California Davis Health, Sacramento, CA, USA.

出版信息

J Neurodev Disord. 2021 Apr 8;13(1):13. doi: 10.1186/s11689-021-09361-6.

Abstract

BACKGROUND

The purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts.

METHOD

Participants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables.

RESULTS

Low rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted.

CONCLUSION

The ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts.

摘要

背景

本研究旨在评估表达性语言取样(ELS)作为唐氏综合征(DS)治疗研究中产生口语语言结果测量的程序。我们解决了以下问题:(a)可行性;(b)两次短期管理之间的练习效应;(c)两次短期管理之间的测试-重测信度;(d)收敛和判别构念效度;(e)考虑了会话和叙述语境之间的比较。

方法

参与者为 107 名年龄在 6 至 23 岁之间、智力残疾(IQ<70)的 DS 患者。分别评估了旨在收集会话和叙述中口语样本的 ELS 程序的实用性。从分段为 C 单元(即独立子句及其修饰语)的文字记录中提取的可交谈性、词汇量、句法、话语规划和发音质量等变量进行了考虑。使用 4 周的间隔来评估练习效应和测试-重测信度。收集了标准化的直接评估和知情者报告措施,以评估 ELS 变量的结构效度。

结果

观察到低不遵守率;年龄在 12 岁以下、具有短语水平的言语或更少言语且发育水平为 4 岁或以下的年轻人特别难以完成 ELS 程序。在 4 周的测试-重测间隔内观察到最小的练习效应和很强的测试-重测信度。词汇量、句法和言语可理解性变量表现出很强的收敛和判别效度。尽管在会话和叙述语境中得出的变量之间发现了显著的相关性,但也注意到了一些差异。

结论

考虑到的 ELS 程序是可行的,并且为大多数年龄在 6 至 23 岁之间的 DS 患者提供了具有足够心理测量特性的变量。话虽如此,仍需要对具有更有限口语技能的 DS 患者的适当结局测量进行研究。ELS 变量中的语境差异表明,当同时使用两种语境时,可能最好获得表达性语言的综合评估。

相似文献

7
Consistency and reliability of automated language measures across expressive language samples in autism.
Autism Res. 2023 Apr;16(4):802-816. doi: 10.1002/aur.2897. Epub 2023 Feb 1.
8
Development of an expressive language sampling procedure in fragile X syndrome: a pilot study.
J Dev Behav Pediatr. 2013 May;34(4):245-51. doi: 10.1097/DBP.0b013e31828742fc.
9
Vocabulary and expressive morpho-syntax in individuals with Down syndrome: Links to narration.
Res Dev Disabil. 2024 Aug;151:104781. doi: 10.1016/j.ridd.2024.104781. Epub 2024 Jun 21.

引用本文的文献

2
Language and Ageing in Adults With Down Syndrome: An Analysis of Receptive and Expressive Language Measures.
J Appl Res Intellect Disabil. 2025 Jan;38(1):e13330. doi: 10.1111/jar.13330.
4
Consistency and reliability of automated language measures across expressive language samples in autism.
Autism Res. 2023 Apr;16(4):802-816. doi: 10.1002/aur.2897. Epub 2023 Feb 1.
6
Considerations for measuring individual outcomes across contexts in Down syndrome: Implications for research and clinical trials.
Int Rev Res Dev Disabil. 2022;62:191-225. doi: 10.1016/bs.irrdd.2022.05.005. Epub 2022 Aug 19.
7
Executive functioning and verbal fluency performance in youth with Down syndrome.
Res Dev Disabil. 2022 Dec;131:104358. doi: 10.1016/j.ridd.2022.104358. Epub 2022 Oct 6.
8
Evaluating Verbal Fluency Outcome Measures in Children With Down Syndrome.
Am J Intellect Dev Disabil. 2022 Jul 1;127(4):328-344. doi: 10.1352/1944-7558-127.4.328.
9
Inclusion of Individuals With Neurodevelopmental Disorders in Norm-Referenced Language Assessments.
Front Psychol. 2022 Aug 12;13:929433. doi: 10.3389/fpsyg.2022.929433. eCollection 2022.

本文引用的文献

2
Children with Down syndrome can benefit from language interventions; Results from a systematic review and meta-analysis.
J Commun Disord. 2020 May-Jun;85:105992. doi: 10.1016/j.jcomdis.2020.105992. Epub 2020 Apr 30.
4
Validation of the NIH Toolbox Cognitive Battery in intellectual disability.
Neurology. 2020 Mar 24;94(12):e1229-e1240. doi: 10.1212/WNL.0000000000009131. Epub 2020 Feb 24.
5
Linguistic Maze Production by Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
J Speech Lang Hear Res. 2020 Jan 16;63(1):274-285. doi: 10.1044/2019_JSLHR-19-00187. Print 2020 Jan 22.
7
Commentary: Measuring Language Change Through Natural Language Samples.
J Autism Dev Disord. 2020 Jul;50(7):2287-2306. doi: 10.1007/s10803-018-3628-4.
8
Narrative Language Sampling in Typical Development: Implications for Clinical Trials.
Am J Speech Lang Pathol. 2018 Feb 6;27(1):123-135. doi: 10.1044/2017_AJSLP-17-0046.
9
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验